Show simple item record

dc.contributor.authorRembielak, Agata
dc.contributor.authorPrice, Patricia M
dc.date.accessioned2009-05-12T16:36:11Z
dc.date.available2009-05-12T16:36:11Z
dc.date.issued2008-02
dc.identifier.citationThe role of PET in target localization for radiotherapy treatment planning. 2008, 31 (1-2):57-62 Onkologieen
dc.identifier.issn1423-0240
dc.identifier.pmid18268401
dc.identifier.doi10.1159/0000112207
dc.identifier.urihttp://hdl.handle.net/10541/67973
dc.description.abstractPositron emission tomography (PET) is currently accepted as an important tool in oncology, mostly for diagnosis, staging and restaging purposes. It provides a new type of information in radiotherapy, functional rather than anatomical. PET imaging can also be used for target volume definition in radiotherapy treatment planning. The need for very precise target volume delineation has arisen with the increasing use of sophisticated three-dimensional conformal radiotherapy techniques and intensity modulated radiation therapy. It is expected that better delineation of the target volume may lead to a significant reduction in the irradiated volume, thus lowering the risk of treatment complications (smaller safety margins). Better tumour visualisation also allows a higher dose of radiation to be applied to the tumour, which may lead to better tumour control. The aim of this article is to review the possible use of PET imaging in the radiotherapy of various cancers. We focus mainly on non-small cell lung cancer, lymphoma and oesophageal cancer, but also include current opinion on the use of PET-based planning in other tumours including brain, uterine cervix, rectum and prostate.
dc.language.isoenen
dc.subjectCanceren
dc.subjectOesophageal Canceren
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshEsophageal Neoplasms
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHumans
dc.subject.meshImage Processing, Computer-Assisted
dc.subject.meshLung Neoplasms
dc.subject.meshLymphatic Irradiation
dc.subject.meshLymphoma
dc.subject.meshNeoplasm Staging
dc.subject.meshNeoplasms
dc.subject.meshPositron-Emission Tomography
dc.subject.meshRadiation Injuries
dc.subject.meshRadiotherapy Planning, Computer-Assisted
dc.subject.meshRadiotherapy, Conformal
dc.subject.meshRadiotherapy, Intensity-Modulated
dc.subject.meshTomography, X-Ray Computed
dc.subject.meshTreatment Outcome
dc.titleThe role of PET in target localization for radiotherapy treatment planning.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Radiation Oncology, Division of Cancer Studies, The University of Manchester, Christie Hospital NHS Trust, Manchester, United Kingdom. agata.rembielak@manchester.ac.uken
dc.identifier.journalOnkologieen
html.description.abstractPositron emission tomography (PET) is currently accepted as an important tool in oncology, mostly for diagnosis, staging and restaging purposes. It provides a new type of information in radiotherapy, functional rather than anatomical. PET imaging can also be used for target volume definition in radiotherapy treatment planning. The need for very precise target volume delineation has arisen with the increasing use of sophisticated three-dimensional conformal radiotherapy techniques and intensity modulated radiation therapy. It is expected that better delineation of the target volume may lead to a significant reduction in the irradiated volume, thus lowering the risk of treatment complications (smaller safety margins). Better tumour visualisation also allows a higher dose of radiation to be applied to the tumour, which may lead to better tumour control. The aim of this article is to review the possible use of PET imaging in the radiotherapy of various cancers. We focus mainly on non-small cell lung cancer, lymphoma and oesophageal cancer, but also include current opinion on the use of PET-based planning in other tumours including brain, uterine cervix, rectum and prostate.


This item appears in the following Collection(s)

Show simple item record